-
Published on Oct 7, 2016
The
head of the Muscular Dystrophy UK charity reckons the recent licensing
deal signed by Summit Therapeutics PLC (LON:SUMM) and Sarepta
Therapeutics (NASDAQ:SRPT) is “very encouraging” for the thousands of
Duchenne Muscular Dystrophy sufferers around the world.
“This is very exciting. Here are two major biotechs coming together and to see Sarepta showing so much confidence in the work of Summit with its product utrophin is very encouraging,” Robert Meadowcroft tells Proactive.
He cautions that the treatment is still a little while away from full approval and commercialisation, but says it offers a sense of hope.
“This move from Sarepta, linking up with Summit, is very encouraging and there is some hope now at last [for DMD sufferers].”
http://www.4-traders.com/SUMMIT-THERAPEUTICS-PLC-18044789/
www.summitplc.com/
Summit presents data on biomarker development at WMS 2016 conference: https://t.co/qyGQW45dkJ— Summit Therapeutics (@Summitplc) October 6, 2016
No comments:
Post a Comment